This statement highlights points made in Professor Salop and Dr. Moresi’s comments on the Update project.
What’s 340B? An economist’s view of the recent wave of 340B litigation
But this change has led to complex relationships among pharmaceutical manufacturers, hospitals, pharmacies, and third-party administrators, increasing...

